Core Insights - NKGen Biotech's troculeucel shows promising cognitive benefits in moderate Alzheimer's patients, with 100% of patients stable or improved and 50% improving from moderate to mild cognitive function [1][4][7] Clinical Data - Pooled analyses from two Phase 1 trials indicate that 92% of patients exhibited stable or improved cognitive function, with dose-responsive trends observed [3][5] - At the three-month assessment, all patients demonstrated stability or improvement across multiple cognitive measures, with higher doses (1 to 6 billion cells) correlating with greater benefits [5][6] - Early signs of durability were noted in patients followed for up to 12 months, with improvements maintained throughout treatment [8] Safety Profile - Troculeucel was well-tolerated, with no treatment-related adverse events reported in the Phase 1 studies [9] Biomarker Correlations - Exploratory plasma GFAP analyses showed strong correlations with clinical measures of disease severity, reinforcing its potential as a non-invasive biomarker for Alzheimer's [10][14] - Baseline plasma GFAP levels correlated significantly with cognitive status, and these correlations remained robust following treatment [14]